Use FDA’s Processes to Speed US Patient Access to Cuban Lung Cancer Vaccine

Medical researchers in Cuba invented a vaccine, called CimaVax-EGF, for lung cancer. CimaVax has been tested in about 7 well-designed clinical trials in patients with advanced non-small-cell lung cancer (NSCLC), and used to treat about 5000 patients over the last 2 decades. This one of a kind vaccine costs about $1 per shot and patients need to take one shot every month. … Read more

GAO Questions FDA’s Post-Marketing Oversight for Drugs Approved via Expedited Programs

A survey conducted by the Government Accountability Office (GAO) found that FDA does not have robust processes to oversee the safety of drugs approved under expedited programs. There are 4 programs under which new drugs can be approved by FDA under reduce testing burden and shorter review times. These programs are priority review, breakthrough therapy designation, accelerated … Read more

Use FDA’s Processes to Speed US Patient Access to Cuban Lung Cancer Vaccine

Medical researchers in Cuba invented a vaccine, called CimaVax-EGF, for lung cancer. CimaVax has been tested in about 7 well-designed clinical trials in patients with advanced non-small-cell lung cancer (NSCLC), and used to treat about 5000 patients over the last 2 decades. This one of a kind vaccine costs about $1 per shot and patients need to take one shot every month. … Read more

Dietary Supplements with Risky Ingredients: Aided by Powerless FDA?

Almost every week FDA make public announcements about dietary supplements with risky ingredients such as unapproved drugs, hidden drug ingredients, dangerous chemicals and other ingredients. FDA’s web-site lists more than 700 such dietary supplements that are sold in the US market. The list is published based on tests conducted at FDA’s labs. However, very few retailers and distributors of … Read more

GMP Sites in China and India: A Comparison

Last week we discussed the similarities and differences between pharmaceutical GMP sites located in China and India with regards to compliance with FDA requirements. This week the Regulatory Affairs Professionals Society (RAPS) published a much more detailed comparison from a different perspective, the review of a few FDA 483s issued to Chinese companies in 2015. Overall country-wide quality of … Read more

Food GMP and Chipotle: PR Stunt or Real Concern 

This Monday Chipotle closed all its stores for 4 hours during peak lunch time to hold a “Virtual” town hall meeting with its employees to “discuss” steps it has taken to improve food safety. Repeated incidences of microbial contamination of food sold at Chipotle outlets lead to more than 500 cases of food borne illnesses last year, leading to … Read more

FDA Drug and Biologic Approval at All Time High

In the year 2015, FDA approved the largest number of new drugs and biologics ever; 45 new drugs and biologics were approved. One third or 36% of these new products were first in class drugs meaning that they had novel mechanisms of action and were chemically and biologically different from any drugs approved in the … Read more

Are GMP Sites in China Better Than Those in India?

India and China have similar number of FDA-registered GMP manufacturing sites, 662 and 694, respectively. India and China manufacture similar kind of regulated products, primarily API and finished drug products, and very few biologics and medical devices. The two countries are culturally and economically quite similar as well. However, manufacturing sites in China have received … Read more

Journals to Require Clinical Trial Data Sharing for Publishing Articles

Clinical trial transparency has been a contentious issue between sponsors of trials wanting to protect their assets, and the other stakeholders, such as trial participants, demanding increased rapid disclosure. Per the clinical trial disclosure laws written in 2007, all clinical trials must be registered and their data published on clinicaltrials.gov. However, the quality of data published on clinicaltrials.gov … Read more